Work / Animation / Idiopathic Pulmonary Fibrosis and the Effects of Treatment
About 50,000 people in the United States are diagnosed with IPF each year. After diagnosis, the estimated survival is only 3 years. Patients with IPF deteriorate to the extent that most die of respiratory failure; essentially their lungs can’t get enough oxygen into their blood.
The animation, developed in partnership with Wedgewood Communications, shows the mechanism of disease for IPF and the mechanism of action for the recently-approved agent OFEV (nintedanib) from Boehringer Ingelheim.
The 6.5-minute animation shows in great detail how the lungs work to get oxygen into the blood, how the lung tissue is repaired when damage occurs, and how this repair process goes awry in IPF.
John Lapolla, Asante Communications, LLC
XVIVO is in a unique class of crackerjack design companies with honest, capable, supremely talented artists, graphic designers, strategists, and project managers, all of whom are committed to excellence in animation. They understand the unique power of this still evolving art form, its ability to distill otherwise unapproachable biochemical data, and to make it available to the untrained marketing professional, all the while preserving the integrity of the science for the experts who have committed their life’s work to drug discovery and development. Ain’t it easy when you know how to do it?